Concepedia

A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies

Stephen K. Williamson, Gary A. Johnson, Holly Maulhardt, D. Scott McMeekin, Thomas K. Schulz, Gregory A. Reed, Katherine F. Roby, Christine B. Mackay, H. John Smith, Scott J. Weir,

Cancer Chemotherapy and Pharmacology · 2015 · 66 citations · 23 references

DOIFull text

Open access

Concepts

References

23

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

, , +8

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · New England Journal of Medicine · 2006 · 2.6K citations · Full text

, , +14

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

David S. Alberts, P. Y. Liu, Edward V. Hannigan et al. · New England Journal of Medicine · 1996 · 1.2K citations · Full text

, , +5

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

Maurie Markman, Brian N. Bundy, David S. Alberts et al. · Journal of Clinical Oncology · 2001 · 1.1K citations

, , +15